Project Grant R01CA300454
Award Date 3/20/26
Completion Date 2/28/31
Dollars Obligated $668K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- Federal Project Grant Award Summary Mayo Clinic received a $484,803 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded August 18, 2025, with a completion date of July 31, 2030. The research project focuses on elucidating glioma risk through integrated analysis of germline and somatic genetic alterations to improve patient outcomes and diagnostic accuracy. The primary research deliverables include: (1) evaluation of...
- Federal Project Grant Award Summary Mayo Clinic received a $161,400 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) for the period August 1, 2025 through July 31, 2027. The award supports research to develop and validate innovative ferroptosis-based therapeutic approaches targeting cholangiocarcinoma (CCA), a highly lethal malignancy of the liver and biliary tract with a five-year survival rate below 10%. The...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant of $658,492 under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a novel targeted combinatorial therapy for advanced castration-resistant prostate cancer (ACRPC). The research, spanning from March 18, 2026 through February 28, 2031, focuses on optimizing the combination of CHK1 inhibitor SRA737 and WEE1 inhibitor AZD1775 to exploit the G2/M...
- Federal Grant Award Summary Massachusetts General Hospital received a $684,107 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 18, 2025, with a completion date of July 31, 2030. The grant supports research into the integration of circulating tumor cell (CTC) and nuclear imaging biomarkers to assess response and resistance to prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT) in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $185,760.00 to The Regents of the University of California, San Francisco under the Cancer Research Manpower program (CFDA 93.398) on July 7, 2025. This Project Grant funds research aimed at enhancing treatment outcomes for metastatic castration-resistant prostate cancer (MCRPC) through the development of novel tumor-targeted combination therapy. The primary research deliverable involves creating a single...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $512,728 Project Grant effective August 1, 2025, through May 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). The award supports development and clinical evaluation of PROBOT, a novel ultrasound probe and robotic system designed to improve image-guided interventions for prostate cancer diagnosis and treatment. The project encompasses a Phase 1...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center $169,776 under the Cancer Research Manpower program (CFDA 93.398) for a two-year project (August 1, 2025–July 31, 2027) titled "Unraveling Myeloid-Mediated Mechanisms of Immunotherapy Resistance in Prostate Cancer Bone Metastases at Single-Cell Resolution." This project grant funds biomedical research training and investigator-initiated research focused on identifying and...
- GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...